Wichmann Matthias W, Müller Christian, Meyer Günther, Strauss Tim, Hornung Hans M, Lau-Werner Ulla, Angele Martin K, Schildberg Friedrich W
Chirurgische und Poliklinik, Klinikum Grosshadern, Ludwig Maximilians Universität, Marchioninistrasse 15, 81377 München, Germany.
Arch Surg. 2002 Feb;137(2):206-10. doi: 10.1001/archsurg.137.2.206.
Preoperative radiochemotherapy for advanced rectal cancer results in fewer lymph nodes detected in the tumor-bearing specimen.
Nonrandomized control trial with analysis of a prospective perioperative database.
Department of Surgery of a large-volume university hospital.
All patients who underwent conventional open surgery to cure rectal cancer between January 1, 1996, and March 31, 2001.
During the study period 184 patients (81%, control group) underwent surgery without receiving preoperative radiochemotherapy. Forty-two patients (19%, study group) who had advanced rectal cancer (modified Dukes stages B [tumors that have penetrated the muscle layer of the bowel wall or have gone through the bowel] or C [tumors that have spread to the lymph nodes in the same region]) received preoperative radiochemotherapy (2 cycles of fluorouracil, 4500 rad) during this period. Most patients underwent anterior rectal resection in both groups (77.7% of those who did not receive preoperative radiochemotherapy and 71.8% of those who did), the remaining patients were treated with abdominoperineal resection.
A mean (SEM) of 19 (1) lymph nodes per specimen were detected in the control patients, while significantly fewer lymph nodes were detected in study patients (13 [1]; P<.05). The rate of inadequate lymph node staging (pNx) increased from 7% in the control group to 12% in the study group (P =.06). Pathological lymph node staging disclosed that significantly more study patients who received preoperative radiochemotherapy had modified Dukes stage A (tumors that are found only in the inner wall or rectum) cancer when compared with the control group (17% vs 0%, respectively; P<.05).
Preoperative radiochemotherapy for advanced rectal cancer results in a significant decrease of lymph nodes detected within the tumor-bearing specimen. Preoperative radiochemotherapy induces significant downstaging with fewer positive lymph nodes and more patients presenting with Dukes stage A rectal cancer. Great care must be taken to remove an adequate number of lymph nodes and more sophisticated pathological techniques of lymph node detection are required since the tumors of ever-increasing numbers of patients are inadequately classified.
晚期直肠癌术前放化疗可使荷瘤标本中检测到的淋巴结数量减少。
对前瞻性围手术期数据库进行分析的非随机对照试验。
一家大型大学医院的外科。
1996年1月1日至2001年3月31日期间所有接受传统开放手术治疗直肠癌的患者。
在研究期间,184例患者(81%,对照组)未接受术前放化疗即接受了手术。42例晚期直肠癌患者(19%,研究组,改良Dukes分期为B期[肿瘤已穿透肠壁肌层或已穿过肠壁]或C期[肿瘤已扩散至同一区域的淋巴结])在此期间接受了术前放化疗(2个周期的氟尿嘧啶,4500拉德)。两组中大多数患者均接受了直肠前切除术(未接受术前放化疗的患者中77.7%接受了该手术,接受术前放化疗的患者中71.8%接受了该手术),其余患者接受了腹会阴联合切除术。
对照组患者每个标本平均(标准误)检测到19(1)个淋巴结,而研究组患者检测到的淋巴结明显较少(13[1];P<0.05)。淋巴结分期不足(pNx)的比例从对照组的7%增加到研究组的12%(P=0.06)。病理淋巴结分期显示,与对照组相比,接受术前放化疗的研究组患者中更多患者的肿瘤为改良Dukes A期(仅在内壁或直肠中发现的肿瘤)(分别为17%和0%;P<0.05)。
晚期直肠癌术前放化疗可使荷瘤标本中检测到的淋巴结数量显著减少。术前放化疗可显著降低分期,阳性淋巴结减少,更多患者表现为Dukes A期直肠癌。由于越来越多患者的肿瘤分期不足,必须谨慎切除足够数量的淋巴结,并需要更复杂的淋巴结检测病理技术。